Sphera Funds Management’s Nautilus Biotechnolgy NAUT Stock Holding History

Sphera Funds Management’s Portfolio NAUT Stock Details NAUT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-840,000	Closed	-$3.65M	–	71
2022 Q1	$3.65M	Buy	840,000 +40,000	+5%	+$164K	0.52%	43
2021 Q4	$4.14M	Hold	800,000	–	–	0.46%	60
2021 Q3	$4.91M	Hold	800,000	–	–	0.41%	68
2021 Q2	$8.08M	Buy	800,000 +400,000	+100%	+$4.33M	0.55%	50
2021 Q1	$5.51M	Hold	400,000	–	–	0.42%	66
2020 Q4	$4.34M	Hold	400,000	–	–	0.39%	75
2020 Q3	$4.29M	Buy	+400,000	New	+$4.27M	0.42%	63

Other funds holding NAUT

AEPBI

AH Equity Partners Bio II Menlo Park, California $144M AUM 54.61% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

MVG

Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CFM

Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return

ACI

Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return

ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return

Sphera Funds Management's NAUT Position: Q2 2022 in Review

Sphera Funds Management sold out of Nautilus Biotechnolgy (NAUT) in Q2 2022, closing a stake of 840,000 shares — an estimated $3.65M sold.

Sphera Funds Management first reported a position in NAUT in Q3 2020 and held it in 7 quarters. The position peaked at $8.08M in Q2 2021. 83 funds tracked by Wall St. Rank hold NAUT as of Q2 2022.

Sphera Funds Management reported no remaining Nautilus Biotechnolgy position as of Q2 2022 after selling out during the quarter.
Sphera Funds Management sold 840,000 Nautilus Biotechnolgy shares in Q2 2022, an estimated $3.65M.
Sphera Funds Management first reported a position in Nautilus Biotechnolgy in Q3 2020 and held it in 7 quarters.
Sphera Funds Management's Nautilus Biotechnolgy position peaked at $8.08M in Q2 2021.
83 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2022.

Based on Sphera Funds Management's 13F filing for Q2 2022, filed 15 Aug 2022.